5 Results for "

noninfectious uveitis

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "noninfectious uveitis" in MCE Product Catalog:

3
Natalizumab (Anti-CD49d)
Natalizumab (Anti-CD49d)
0 Images
3 Cited Publications
Cat. No.: HY-108831A
CAS No.: 189261-10-7
Purity:  98.72%
Synonyms: AN100226; BG00002

Target:  

Integrin

Research Areas:  

Neurological Disease Inflammation/Immunology Cancer

Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
loading...
    loading...
View All Sizes
3
Natalizumab
Natalizumab
0 Images
3 Cited Publications
Cat. No.: HY-108831
CAS No.: 189261-10-7
Purity:  99.10%

Target:  

Integrin

Research Areas:  

Neurological Disease Inflammation/Immunology Cancer

Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
loading...
    loading...
View All Sizes
Reproxalap
Reproxalap
0 Images
Cat. No.: HY-107150
CAS No.: 916056-79-6
Purity:  98.85%
Synonyms: ADX-102; NS-2
Target:  

PKC Caspase

Research Areas:  

Neurological Disease Inflammation/Immunology

Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis .
loading...
    loading...
View All Sizes
Vamikibart
Vamikibart
0 Images
Cat. No.: HY-P990012
CAS No.: 2744320-12-3
Synonyms: EBI-031

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Vamikibart (EBI-031) is a humanized IgG2κ monoclonal antibody targeting IL-6, with high binding affinity for IL-6 and the IL-6/IL-6R complex. Vamikibart reduces central retinal thickness, resolves intraretinal and subretinal foveal fluid, and decreases the levels of intraocular inflammatory markers. Vamikibart can be used in studies of uveitic macular edema (UME) secondary to non-infectious uveitis .
loading...
    loading...
View All Sizes
Reproxalap (Standard)
Reproxalap (Standard)
0 Images
Cat. No.: HY-107150R
CAS No.: 916056-79-6
Synonyms: ADX-102 (Standard); NS-2 (Standard)
Target:  

Reference Standards PKC Caspase

Research Areas:  

Neurological Disease Inflammation/Immunology

Reproxalap (Standard) (ADX-102 (Standard)) is the analytical standard of Reproxalap (HY-107150). This product is intended for research and analytical applications. Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis .
loading...
    loading...
View All Sizes
Assay Types